Subscribe To
PRDS / Pardes Biosciences Clears IND Application For Oral Antiviral Candidate For COVID-19
PRDS News
By Market Watch
July 17, 2023
Pardes Biosciences stock rallies on buyout offer from MediPacific
Pardes Biosciences Inc.'s PRDS, -0.54% stock was up 12.4% in premarket trades Monday after the clinical-stage biopharmaceutical company said it agreed more_horizontal
By Zacks Investment Research
June 5, 2023
All You Need to Know About Pardes Biosciences, Inc. (PRDS) Rating Upgrade to Buy
Pardes Biosciences, Inc. (PRDS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This m more_horizontal
By Seeking Alpha
May 17, 2023
Pardes Biosciences Seeking Strategic Alternatives
Pardes Biosciences Seeking Strategic Alternatives. Pardes' Pipeline is depleted. more_horizontal
By GlobeNewsWire
March 21, 2022
Pardes Biosciences to Present at the International Conference On Antiviral Research 2022
CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing P more_horizontal
By Benzinga
February 14, 2022
Pardes Biosciences Shares Early Data From COVID-19 Study
Pardes Biosciences Inc's (NASDAQ: PRDS) has presented interim data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers at the Confe more_horizontal
By Benzinga
February 14, 2022
Pardes Biosciences Shares Early Data From COVID-19 Study
Pardes Biosciences Inc's (NASDAQ: PRDS) has presented interim data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers at the Confe more_horizontal
By Benzinga
February 14, 2022
Pardes Biosciences Shares Early Data From COVID-19 Study
Pardes Biosciences Inc's (NASDAQ: PRDS) has presented interim data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers at the Confe more_horizontal
By Benzinga
February 3, 2022
Pardes Biosciences Clears IND Application For Oral Antiviral Candidate For COVID-19
The FDA has signed off Pardes Biosciences Inc's PRDS Investigational New Drug (IND) application for PBI-0451 for COVID-19. Get the Inside Access Tr more_horizontal